Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian Cancer

NCT03126812 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT03126812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03126812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian Cancer
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 1/2
Overall status
Completed
Start date
November 1, 2017
Completion date
March 5, 2024
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer stage iv, peritoneal cancer